Epstein syndrome (disorder)
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
Epstein syndrome nephropathy due to a severe MYH9 gene mutation can be refractory and progress rapidly; therefore, early and accurate diagnosis is important for safer therapeutic options including pre-emptive renal transplantation.
|
29532554 |
2019 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
CLINGEN |
R705H mutation of MYH9 is associated with MYH9-related disease and not only with non-syndromic deafness DFNA17.
|
24890873 |
2015 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
CLINGEN |
c.G2114A MYH9 mutation (DFNA17) causes non-syndromic autosomal dominant hearing loss in a Brazilian family.
|
25505834 |
2014 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
CLINGEN |
Establishment of mouse model of MYH9 disorders: heterozygous R702C mutation provokes macrothrombocytopenia with leukocyte inclusion bodies, renal glomerulosclerosis and hearing disability.
|
23976996 |
2013 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
CLINGEN |
Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.
|
21908426 |
2012 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
MGD |
Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A.
|
21908426 |
2012 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
CLINGEN |
Recent advances in the understanding and management of MYH9-related inherited thrombocytopenias.
|
21542825 |
2011 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
BEFREE |
Genetic studies confirmed mutations in the gene encoding the myosin heavy chain (MYH-9), and Epstein Syndrome was diagnosed.
|
19839854 |
2009 |
Epstein syndrome (disorder)
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
MYH9 R702 mutations are highly associated with Alport manifestations and result in Epstein syndrome.
|
17241369 |
2007 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
BEFREE |
Hereditary thrombocytopenias characterized by mutations in the gene for non-muscle myosin heavy chain IIA (NMMHC-IIA) are known as MYH9-related hereditary macrothrombocytopenia, and include the May-Hegglin anomaly, Sebastian platelet syndrome, Fechtner syndrome, and Epstein syndrome.
|
17655694 |
2007 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
CLINGEN |
Cochlear implants for DFNA17 deafness.
|
17146397 |
2006 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
CLINGEN |
Expression of Myh9 in the mammalian cochlea: localization within the stereocilia.
|
16862555 |
2006 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
CLINGEN |
Absence of hearing loss in a mouse model for DFNA17 and MYH9-related disease: the use of public gene-targeted ES cell resources.
|
16630581 |
2006 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
CLINGEN |
Rod mutations associated with MYH9-related disorders disrupt nonmuscle myosin-IIA assembly.
|
15339844 |
2005 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
CLINGEN |
Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations.
|
16162639 |
2005 |
Epstein syndrome (disorder)
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
We identified a MYH9 missense mutation in two EPTS familial cases.
|
11935325 |
2002 |
Epstein syndrome (disorder)
|
0.560 |
GeneticVariation
|
disease |
BEFREE |
Moreover, it is demonstrated that MYH9 mutations also result in two other FTNS-like macrothrombocytopenia syndromes: Epstein syndrome (EPS) and Alport syndrome with macrothrombocytopenia (APSM).
|
11590545 |
2001 |
Epstein syndrome (disorder)
|
0.560 |
Biomarker
|
disease |
CLINGEN |
A five-generation family with late-onset progressive hereditary hearing impairment due to cochleosaccular degeneration.
|
9390828 |
1998 |